secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2022-02-25T23:59:59+00:00
Accession:  0001654954-22-002090
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zivo Bioscience terminates CEO Andrew Dahl for cause; Dahl resigns from board
-----------------------------------------------------------------------------

- CEO Andrew A. Dahl terminated for cause on Jan 4, 2022 after declining to resign; no separation agreement reached.
- On Feb 18, 2022, Dahl resigned from the board of directors; board size reduced to four members.
- Principal executive office moved to 21 E. Long Lake Road, Suite 100, Bloomfield Hills, MI effective Feb 21, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422002090/0001654954-22-002090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422002090/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-002090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer